Swan Genomics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 7

Swan Genomics General Information

Description

Operator of a biotechnology company intended to commercialize an approach to DNA sequencing to deliver accessible genomics data. The company uses plasmonic nanoantenna for precision nanoscale sensor positioning at the manufacturing scale, engineered optical hotspot to make single fluorescent molecules thousands of times brighter, and to read bases one at a time as optical pulses in real time from a single molecule, enabling healthcare professionals to get a single platform for accessing the complete molecular picture.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Sydney, New South Wales 2075
  • Australia
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Other Healthcare Technology Systems
Corporate Office
  • Sydney, New South Wales 2075
  • Australia

Swan Genomics Timeline

202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Swan Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 01-Aug-2024 Completed Generating Revenue
2. Accelerator/Incubator 01-May-2023 Completed Generating Revenue
1. University Spin-Out 01-Jan-2023 Completed Generating Revenue
To view Swan Genomics’s complete valuation and funding history, request access »

Swan Genomics Patents

Swan Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026170259-A1 Systems and methods for analyte processing Pending 14-Feb-2025
AU-2024903139-A0 Fluorescence enhancement using quenchers Pending 30-Sep-2024
WO-2026069007-A2 Fluorescence enhancement using quenchers Pending 27-Sep-2024
WO-2026069007-A3 Fluorescence enhancement using quenchers Pending 27-Sep-2024
AU-2024267511-A1 "plasmonic nanoantenna and use of same in single molecule sequencing" Pending 08-May-2023 C12Q1/6869
To view Swan Genomics’s complete patent history, request access »

Swan Genomics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
EGB Capital (California) Venture Capital Minority
In-Q-Tel Not-For-Profit Venture Capital Minority
Investible Venture Capital Minority
Ki Tua Fund Corporate Venture Capital Minority
Pacific Channel Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Swan Genomics FAQs

  • When was Swan Genomics founded?

    Swan Genomics was founded in 2023.

  • Where is Swan Genomics headquartered?

    Swan Genomics is headquartered in Sydney, Australia.

  • What industry is Swan Genomics in?

    Swan Genomics’s primary industry is Biotechnology.

  • Is Swan Genomics a private or public company?

    Swan Genomics is a Private company.

  • What is Swan Genomics’s current revenue?

    The current revenue for Swan Genomics is .

  • How much funding has Swan Genomics raised over time?

    Swan Genomics has raised $2M.

  • Who are Swan Genomics’s investors?

    EGB Capital (California), In-Q-Tel, Investible, Ki Tua Fund, and Pacific Channel are 5 of 7 investors who have invested in Swan Genomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process